Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics announced that its Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy for first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC) met its primary endpoint of progression-free survival at planned interim analysis. The results will be presented in a Presidential Symposium at th…